P&PAULSON & CO. INC.
Institutional investor · Portfolio as of Q1 2025
Top Holdings14 positions
MADRIGAL PHARMACEUTICALS INC | 2.1M | $695.4M | 39.8% | $239.32 | +38.40% | 8 qtrssince 2023-Q2 | Increased 66 |
PERPETUA RESOURCES CORP | 24.8M | $264.8M | 15.2% | $5.90 | +81.15% | 17 qtrssince 2021-Q1 | Unchanged 0 |
ACADIAN ASSET MANAGEMENT INC | 9M | $231.5M | 13.3% | $9.52 | +170.22% | 23 qtrssince 2019-Q3 | Unchanged 0 |
BAUSCH HEALTH COS INC | 26.4M | $171.1M | 9.8% | $20.87 | -69.00% | 23 qtrssince 2019-Q3 | Unchanged 0 |
AGNICO EAGLE MINES LTD | 783,561 | $84.9M | 4.9% | $55.39 | +92.83% | 13 qtrssince 2022-Q1 | Unchanged 0 |
NOVAGOLD RESOURCES INC | 27.2M | $79.5M | 4.6% | $5.68 | -48.57% | 23 qtrssince 2019-Q3 | Unchanged 0 |
THRYV HOLDINGS INC | 4.3M | $54.8M | 3.1% | $14.19 | -9.74% | 18 qtrssince 2020-Q4 | Unchanged 0 |
INTERNATIONAL TOWER HILL MIN | 70.2M | $44.4M | 2.5% | $0.56 | +12.12% | 23 qtrssince 2019-Q3 | Increased 58 |
HONEYWELL INTL INC | 200,000 | $42.4M | 2.4% | $203.19 | 0.00% | 1 qtr | New 78 |
SEABRIDGE GOLD INC | 2.1M | $24.2M | 1.4% | $17.38 | -32.84% | 23 qtrssince 2019-Q3 | Unchanged 0 |
TRILOGY METALS INC NEW | 14.3M | $22.2M | 1.3% | $1.66 | -6.63% | 23 qtrssince 2019-Q3 | Unchanged 0 |
EQUINOX GOLD CORP | 2.5M | $17.2M | 1.0% | $11.17 | -38.68% | 20 qtrssince 2020-Q2 | Unchanged 0 |
IAMGOLD CORP | 1.9M | $11.6M | 0.7% | $3.41 | +83.28% | 23 qtrssince 2019-Q3 | Unchanged 0 |
INTRA-CELLULAR THERAPIES INC | 21,500 | $2.8M | 0.2% | — | — | 1 qtr | New 47 |
PAULSON & CO. INC. manages $1.7B across 14 positions as of Q1 2025. Top holdings: MDGL (39.8%), PPTA (15.2%), AAMI (13.3%). Fund DNA: Concentrated Value. HoldingsIntel Score: 2.5/5.0.
Added 2 new positions, exited 1, increased 2. Top move: HON (NEW, conviction 78). Portfolio: $1.7B across 14 positions.
Top holdings by portfolio weight
Portfolio allocation by GICS sector
Behavioral investing profile
Position Outcomes
Best and worst performing positions by estimated return
Top Winners
Top Losers
Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.
Similar Funds
Funds with similar investing DNA
Explore More
Accumulation Streaks
Positions with 2+ consecutive quarters of increases - persistent directional conviction.
Continue exploring
Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer
Verify source filings on SEC EDGAR